Therefore, Sema3A has recently been recognized as a new paradigm in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and multiple sclerosis (MS). Here, SEMA3A is linked to systemic lupus erythematosus.